Nathan Congdon, MD, highlights a recent study showing how virtual mentor-mentee relationships through Orbis' free ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related macular ...

The risk of systemic side effects is greater in infants than in adults due to increased percutaneous drug absorption and lower blood volume. The closed eyes technique of eyedrop administration is ...